Latest kidney cancer news
17 May 2022
Neoadjuvant axitinib may enable partial nephrectomy of complex kidney tumours
17 May 2022
Quality of life on lenvatinib plus pembrolizumab combination
16 May 2022
Transforming lives, raising productivity
13 May 2022
Tougher cancer diagnostic target as part of government's 'war on cancer'
12 May 2022
Breakthrough COVID-19 infections in vaccinated cancer patients
11 May 2022
MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer
11 May 2022
Treatment of local recurrence of kidney cancer after nephrectomy
3 May 2022
Treatment of people who relapse on adjuvant pembrolizumab
3 May 2022
Moderna’s COVID-19 vaccine may be more effective for cancer patients
3 May 2022
Kidney cancer patient summit on immunotherapy/TKI combinations
27 Apr 2022
Metastasectomy and survival in kidney cancer patients
26 Apr 2022
Cabozantinib for collecting duct carcinoma
A recent study, the health-related quality of life (HRQoL) of patients in the phase 3 CLEAR study are discussed. All 1069 patients in the study were followed up for just over a year for quality of life assessments.
Read more on our website: https://t.co/JXoisK7EAk
#kidneycancer https://t.co/NoRUmJ9phy
Read more on our website: https://t.co/JXoisK7EAk
#kidneycancer https://t.co/NoRUmJ9phy
The Association of the British Pharmaceutical Industry (ABPI) has commissioned a report about access to medicines in the UK. The NHS has made progress. However, access to medicines in the UK remains poor, especially compared to other developed countries. https://t.co/uWZz5ZL7zn https://t.co/zWIlei5wLR
O is for Our real stories
We are looking for people to share their experience of living with kidney cancer, or if you have been on a clinical trial, or you have a loved one living with a #kidneycancer diagnosis with us, for our real stories page.
https://t.co/Y2sUh84XXc https://t.co/gXAfsYixjq
We are looking for people to share their experience of living with kidney cancer, or if you have been on a clinical trial, or you have a loved one living with a #kidneycancer diagnosis with us, for our real stories page.
https://t.co/Y2sUh84XXc https://t.co/gXAfsYixjq
Save the date 16 June 2022 to take part in World Kidney Cancer Day and raise awareness of clinical trials and access to treatments for #kidneycancer patients.
To improve the lives of patients worldwide ‘We need to talk’.
For more info:
https://t.co/wPwUYXhRFR https://t.co/LLSlAXcEtF
To improve the lives of patients worldwide ‘We need to talk’.
For more info:
https://t.co/wPwUYXhRFR https://t.co/LLSlAXcEtF
N is for newsletter
Our newsletter is easy to read, friendly, and provides information about #kidneycancer.
If you would like to receive a copy via email, please subscribe by completing the form at the bottom of the web page below #bypatientsforpatients
https://t.co/qbOpq9qguP https://t.co/kFehdRCDC6
Our newsletter is easy to read, friendly, and provides information about #kidneycancer.
If you would like to receive a copy via email, please subscribe by completing the form at the bottom of the web page below #bypatientsforpatients
https://t.co/qbOpq9qguP https://t.co/kFehdRCDC6
The aim of a phase 2 study was to compare MEDI0680 plus durvalumab with nivolumab in #kidneycancer patients who had not been treated with immunotherapy before, but who had been treated with a targeted therapy.
To find out more about the study: https://t.co/eB1EOd694l https://t.co/HiGploabQ6
To find out more about the study: https://t.co/eB1EOd694l https://t.co/HiGploabQ6
This study is looking at a new combination of two medicines called cyclophosphamide and pembrolizumab for the treatment of people with kidney cancer (renal cell carcinoma, RCC) that is not possible to remove with an operation or has spread to other parts of the body.
Just over half of the patients from a phase 2 clinical trial looking at giving axitinib to shrink the kidney cancer tumour before surgery (neoadjuvant axitinib) have been looked at. In these 26 patients, kidney tumour size and complexity were significantly reduced. This enabled the patients to have....
In this study, the health-related quality of life (HRQoL) of patients in the phase 3 CLEAR study are discussed. There were 355 patients on lenvatinib plus pembrolizumab; 357 patients on lenvatinib plus everolimus; and 357 patients on sunitinib in the CLEAR study. All were followed up for just over a...
The Association of the British Pharmaceutical Industry (ABPI) has commissioned a report about access to medicines in the UK. The NHS has made progress towards making some of the most exciting new medicines and vaccines available to patients. However, the report shows that access to medicines in the....
The following was published in the Health Services Journal (HSJ) today: Government is considering setting a tougher cancer diagnostic target as part of its declared ‘war on cancer’, HSJ has been told. Sajid Javid announced a “war on cancer” and launched a call for evidence on what could be d...
